CGTLive®’s Weekly Rewind – January 16, 2026

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. FDA Hits Atara Biotherapeutics’ T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD With Second CRL

The CRL indicates that the ALLELE clinical trial does not sufficiently show efficacy of the product.

2. Angela Lek, PhD, on the Priorities and Agenda for MDA's 2026 Conference

The chief research officer of the Muscular Dystrophy Association discussed emerging scientific priorities and community-driven initiatives shaping the organization's 2026 Clinical and Scientific Conference.

3. Therapies to Watch in 1H 2026

We highlighted a few investigational cell and gene therapy candidates to keep an eye on in the first half of the new year.

4. Steven W. Pipe, MD, on Integrating Gene Therapy into Clinical Care for Hemophilia B

The professor of pediatric hematology/oncology at the University of Michigan Health discussed what clinics need in order to start administering Hemgenix effectively.

5. Data Roundup: December 2025 Features Updates from ASH and CTAD

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive team.